Market Place
Sourcing Support
Applied DNA Rebrands To BNB Plus Corp., Elects Josh Kruger
17 Nov 2025 //
BUSINESSWIRE
Applied DNA Closes $58M Private Placement, BNB Valued at $17M
22 Oct 2025 //
BUSINESSWIRE
Applied DNA To Report Q1 Fiscal 2025 Results On Feb 13
12 Feb 2025 //
ACCESSWIRE
Applied DNA Regains Nasdaq Minimum Bid Price Compliance
18 Sep 2024 //
ACCESSWIRE
Applied DNA Signs CertainT Cotton Traceability Deal With Indus Group
25 Jul 2024 //
ACCESSWIRE
US Defense Logistics Agency Extends Applied DNA`s Counterfeit Contract
18 Jul 2024 //
ACCESSWIRE
SpendMend`s Trulla Optimizes Pharmacy Procurement At Froedtert Health
13 Jun 2024 //
ACCESSWIRE
Applied DNA to Establish First Enzymatic cGMP DNA Manufacturing Capacity
24 Oct 2022 //
BUSINESSWIRE
Applied DNA Announces Receipt of Largest Single Purchase Order for LinearDNA
10 Oct 2022 //
BUSINESSWIRE
Applied DNA’s Subsidiary Publishes that a LinearDNA Vaccine Candidate
30 Sep 2022 //
BUSINESSWIRE
Applied DNA to Present at the H.C. Wainwright Global Investment Conference
07 Sep 2022 //
BUSINESSWIRE
Applied DNA Launches Monkeypox Testing Service
06 Sep 2022 //
BUSINESSWIRE
Applied DNA Submits PCR-based Monkeypox Virus Diagnostic Test for Approval
19 Aug 2022 //
BUSINESSWIRE
Applied DNA Reports Third Quarter Fiscal 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Applied DNA Biotherapeutics Subsidiary Reports LinearDNA™ Platform Development Milestone
10 Aug 2022 //
PRESS RELEASE
Applied DNA Announces Pricing of $12 Million Upsized Public Offering
04 Aug 2022 //
BUSINESSWIRE
Applied DNA Initiates Analytical Validation of PCR-based Diagnostic Test
02 Aug 2022 //
BUSINESSWIRE
LineaRx and EvviVax Publish Additional Proof-of-Concept Data on LinearDNA
25 Jul 2022 //
BUSINESSWIRE
LineaRx to Present Data on Advantages of its Enzymatically Produced LinearDNA
22 Jul 2022 //
BUSINESSWIRE
Applied DNA Launches Initiatives to Expand Awareness of LinearDNA Platform
29 Jun 2022 //
BUSINESSWIRE
Applied DNA to Participate in Fireside Chat at 34th ROTH Conference
10 Mar 2022 //
BUSINESSWIRE
Applied DNA Announces Closing of $4.2 Million Registered Direct Offering
24 Feb 2022 //
BUSINESSWIRE
Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering
22 Feb 2022 //
BUSINESSWIRE
Applied DNA Q1 Fiscal 2022 Financial Results Feature Record Quarterly Revenues
10 Feb 2022 //
BUSINESSWIRE
Applied DNA to Deploy Linea 1.0 COVID-19 Assay for Rapid Detection of BA.2
28 Jan 2022 //
BUSINESSWIRE
Applied DNA Submits Request for EUA to FDA for Linea 2.0 COVID-19 Assay
21 Jan 2022 //
BUSINESSWIRE
Applied DNA Receives NYSDOH Conditional Approval for Linea 2.0 COVID-19 Assay
04 Jan 2022 //
BUSINESSWIRE
Applied DNA to introduce Linea 2.0 assay kit to address Omicron
29 Nov 2021 //
PHARMABIZ
Applied DNA, CLEARED4 Offer Fast, Cost-Effective and Turnkey Integrated Solution
05 Nov 2021 //
BUSINESSWIRE
Applied DNA Submits Request for EUA to FDA for Linea SARS-CoV-2 Mutation Panel
25 Oct 2021 //
BUSINESSWIRE
Applied DNA to Participate at H.C. Wainwright Global Investment Conference
07 Sep 2021 //
BUSINESSWIRE
Applied DNA Schedules Fiscal 2021 Third Quarter Financial Results
05 Aug 2021 //
BUSINESSWIRE
Applied DNA Awarded The City University of New York COVID-19 Testing Contract
04 Aug 2021 //
BUSINESSWIRE
Applied DNA Announces Data on its vaccine
07 Jun 2021 //
BUSINESSWIRE
Applied DNA Completes Technical Validation of PCR-based SARS-CoV-2 Mutation
26 May 2021 //
BUSINESSWIRE
Applied DNA and Evvivax Announce Positive Preliminary Results of Ph I Trial
13 Apr 2021 //
BUSINESSWIRE
Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability
08 Apr 2021 //
BUSINESSWIRE
Applied DNA Launches Linea™ COVID-19 Selective Genomic Surveillance™
09 Mar 2021 //
BUSINESSWIRE
Applied DNA to Provide Back-To-Campus COVID-19 Surveillance Testing to LIM
19 Feb 2021 //
BUSINESSWIRE
Applied DNA and Cytocheck Detect First Instance of SARS-CoV-2 B.1.1.7
11 Feb 2021 //
BUSINESSWIRE
Applied DNA Partners with CLEARED4 on Pooled COVID-19 Surveillance Program
29 Dec 2020 //
BUSINESSWIRE
Applied DNA, EvviVax, & GVS Receive Regulatory Approval to Clinical Trial
30 Nov 2020 //
BUSINESSWIRE
Applied DNA to Increase COVID-19 Surveillance Testing Utility for its Linea™
30 Oct 2020 //
BUSINESSWIRE
Applied DNA Announces Repayment of Secured Convertible Notes
08 Oct 2020 //
BUSINESSWIRE
Applied DNA Agreement with SBU Hospital for COVID-19 Diagnostic Assay Kit
29 Sep 2020 //
BUSINESSWIRE
Applied DNA, Takis announce positive preclinical results from LineaDNA
18 Jul 2020 //
PHARMABIZ
Applied amends investor deck, bolstering accusations made by anonymous
13 Jul 2020 //
STATNEWS
Applied DNA & Takis Biotech Announce the Production of Neutralizing Antibodies
04 May 2020 //
BUSINESSWIRE
Applied DNA Accepted Into USFDA’s Emerging Technology Program, Creating Pathway
30 Apr 2020 //
BUSINESSWIRE
Applied DNA Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Devp Partner
15 Apr 2020 //
BUSINESSWIRE
Applied DNA Leverages COVID-19 Vaccine Development & Proprietary Linear DNA mfg
19 Mar 2020 //
BUSINESSWIRE
Applied DNA Receives Initial $1 Million Payment from TheraCann International
24 Apr 2019 //
BUSINESSWIRE
Applied DNA Subsidiary Agreement with Takis to Develop Anti-Cancer Vaccines
20 Sep 2018 //
BUSINESSWIRE
Applied DNA Announces $1.65 mln Private Placement
03 Sep 2018 //
BUSINESSWIRE
Applied DNA Sciences Reaches New Milestones in Contract Manufac of Linear DNA
02 Aug 2018 //
BIOSPACE
Colorcon and Applied DNA Sciences sign tech MOU
20 Dec 2017 //
IN PHARMATECHNOLOGIST
Applied DNA Sciences introduces SigNature DNA in new pharmaceutical-grade
25 Feb 2016 //
CPHI ONLINE
